Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992144 | 0.87 | AKR1C3 (0.37) | EPHX2PPARGAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL4989456 | 0.85 | PPARG (0.43) | EPHX2PPARGAKR1C3AKR1C2POLB | |
| SCHEMBL4986187 | 0.85 | AKR1C3 (0.40) | EPHX2PPARGAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL4981498 | 0.85 | EPHX2 (0.39) | EPHX2PPARGAKR1C3AKR1C2POLB | |
| SCHEMBL4986459 | 0.83 | PPARG (0.40) | EPHX2PPARGAKR1C3AKR1C2AKR1C4 | |
| SCHEMBL27644194 | 0.83 | AKR1C3 (0.40) | AKR1C3AKR1C2POLBMAPK1CTSS | |
| SCHEMBL4993489 | 0.82 | AKR1C3 (0.36) | AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL4991651 | 0.81 | PPARG (0.37) | EPHX2PPARGAKR1C3AKR1C2AKR1C4 | |
| SCHEMBL4991258 | 0.81 | PPARG (0.44) | EPHX2PPARGAKR1C3AKR1C2PPARA | |
| SCHEMBL4993490 | 0.80 | SLC1A1 (0.35) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | EPHX2 3970/4885PPARG 1820/4885AKR1C3 4710/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | EPHX2 3738/4885PPARG 1405/4885AKR1C3 4658/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | EPHX2 3738/4885PPARG 1828/4885AKR1C3 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.